Form 4: Madrigal Director Exercises Options, Sells Shares

Madrigal Pharmaceuticals Director Paul A. Friedman exercised stock options and sold a significant number of shares in pre-planned transactions.

Summary

• Director Paul A. Friedman exercised stock options to acquire 3,203 shares on August 11, 2025, and 43,605 shares on August 12, 2025, both at an exercise price of $9.45 per share.
• On August 11, 2025, Friedman sold a total of 3,203 shares of common stock at weighted average prices of $350.1911 and $351.0411.
• On August 12, 2025, Friedman sold a total of 43,605 shares of common stock at weighted average prices ranging from $350.9272 to $359.81.
• All sales were conducted under a Rule 10b5-1 trading plan adopted on March 14, 2025.
• Following these transactions, Friedman directly beneficially owns 187,164 shares of common stock.
• Friedman also indirectly beneficially owns 655,540 shares through SQN LLC, where he and his spouse are managing members, disclaiming ownership except for pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the fact that these sales were pre-planned under a Rule 10b5-1 plan mitigates concerns about a lack of confidence. The director also realized significant gains from option exercises, which is a positive for the individual.

Positives

• The exercise of stock options at a low price ($9.45) and subsequent sale at significantly higher prices (ranging from $350.19 to $359.81) indicates substantial personal profit for the director.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, suggesting a systematic approach to managing equity rather than a reaction to new negative information.

Negatives

• The sale of a significant number of shares by a director could be perceived by some investors as a reduction in insider confidence, although the 10b5-1 plan mitigates this interpretation.

Risks

• The reporting person disclaims beneficial ownership of shares held indirectly through SQN LLC, except to the extent of his pecuniary interest, which could introduce complexity in assessing total insider exposure.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details routine insider transactions, specifically the exercise of stock options and subsequent sale of shares by a director. Such transactions are common for executives managing their equity compensation and typically do not reflect broader industry trends or competitive shifts, unless they are unusually large or outside of a pre-planned trading schedule.

Related Party Transactions

• Paul A. Friedman and his spouse are managing members of SQN LLC, which indirectly holds 655,540 shares of Madrigal Pharmaceuticals common stock. Friedman disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even if pre-planned, might lead to minor short-term sentiment shifts, but the overall impact is likely minimal given the routine nature of 10b5-1 transactions. The director retains a significant direct and indirect stake.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this insider trading report.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the completion of these transactions.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (option exercise and sale) executed under a pre-planned Rule 10b5-1 trading plan. Such transactions are typically for personal financial management and do not inherently signal a change in the company's fundamental outlook or performance. Therefore, based solely on this filing, there is no new information to warrant a change in investment recommendation; a 'hold' stance is appropriate as the filing does not provide insights into the company's operational or strategic performance.

Keywords

Madrigal Pharmaceuticals, MDGL, SEC Form 4, Insider Trading, Stock Options, Share Sale, Director Transactions, Rule 10b5-1 Plan, Paul A. Friedman